Verastem's VS-7375 Shows Strong Anti-Tumor Activity in KRAS G12D-Mutant Cancers
Verastem Oncology (VSTM) announced positive early efficacy results for its experimental cancer drug, VS-7375. The drug demonstrated confirmed objective response rates of up to 50% at a dose of 900 mg once daily in patients with advanced KRAS G12D-mutated solid tumors who were treated as second-line therapy. KRAS mutations are common across various cancers and historically difficult to target, making VS-7375's performance notable. The results suggest potential for the drug to become a key treatment option for this patient population in future clinical practice or trials. The data could influence investor sentiment toward Verastem as it progresses with further development of VS-7375 and may attract interest from pharmaceutical partners seeking innovative oncology therapies.
Topics: Drug Development KRAS Mutations Oncology Pharmaceuticals